Results 201 to 210 of about 49,422 (253)
Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma. [PDF]
Curr OncolHuang J, Ojo A, Liaw B.
europepmc +1 more source
Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma. [PDF]
Front OncolBertuglia G +5 more
europepmc +1 more source
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. [PDF]
J Hematol OncolLu N, Yan B, Li YQ, Wan JL.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
BATT DAVID BRYANT +7 more
+22 more sources
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
BATT DAVID BRYANT +7 more
+22 more sources
Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
ABRAMS TINYA +8 more
openaire +7 more sources
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
ABRAMS TINYA +8 more
openaire +7 more sources
Antibody–drug conjugates for cancer
The Lancet, 2019Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Cindy H, Chau +2 more
openaire +2 more sources
Antibody–Drug Conjugates for Immunology
Journal of Medicinal Chemistry, 2022The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire +2 more sources
Antibody–Drug Conjugates in Uro-Oncology
Targeted Oncology, 2022Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment.
Dawid Sigorski +3 more
openaire +2 more sources
The Promise of Antibody–Drug Conjugates
New England Journal of Medicine, 2012The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and ...
Beverly A, Teicher, James H, Doroshow
openaire +2 more sources